Issues
-
Cover Image
Cover Image
Exercise can impact immune responses to cancer, but the mechanisms behind this are not fully understood. Gomes-Santos et al. demonstrate in murine models of breast cancer that exercise training contributes to tumor control and response to immune checkpoint blockade (ICB). Mechanistically, exercise training induces vessel normalization, increases effector immune cell infiltration and function, and controls tumor growth in a CXCR3 signaling/CD8+ T cell–dependent manner. Because of these effects, ICB-refractory breast cancer becomes sensitized to treatment. Exercise also reduces the incidence of lung metastasis. The data support the use of exercise training to improve antitumor responses and immunotherapy efficacy. Read more in this issue on page 765. Original image from Fig. 2G. Artwork by Lewis Long. - PDF Icon PDF LinkTable of Contents
- PDF Icon PDF LinkEditorial Board
Cancer Immunology Research
Cancer Immunology Research, launched in 2013 with Glenn Dranoff as founding Editor-in-Chief, is published by the AACR. The Journal illuminates the interplay between tumors and the immune system, with Robert D. Schreiber and Philip D. Greenberg serving as the Editors-in-Chief.
Table of Contents
What We’re Reading
In the Spotlight
Priority Brief
Regulatory T-cell Transcriptomic Reprogramming Characterizes Adverse Events by Checkpoint Inhibitors in Solid Tumors
Research Articles
Host IL11 Signaling Suppresses CD4+ T cell–Mediated Antitumor Responses to Colon Cancer in Mice
MHC Class II Antigen Presentation by Lymphatic Endothelial Cells in Tumors Promotes Intratumoral Regulatory T cell–Suppressive Functions
Exercise Training Improves Tumor Control by Increasing CD8+ T-cell Infiltration via CXCR3 Signaling and Sensitizes Breast Cancer to Immune Checkpoint Blockade
The Chemokine CX3CL1 Improves Trastuzumab Efficacy in HER2 Low–Expressing Cancer In Vitro and In Vivo
Mechanisms Driving Neutrophil-Induced T-cell Immunoparalysis in Ovarian Cancer
T Cells Expressing Receptor Recombination/Revision Machinery Are Detected in the Tumor Microenvironment and Expanded in Genomically Over-unstable Models
Journal Archive
Cancer Immunology Research
(2013-Present)Published monthly since 2013.
(ISSN 2326-6066)
Cancer Immunity
(2001-2013; volumes 1-13)Published periodically from 2001-2013.
(EISSN 1424-9634)
Advertisement
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale—within the United States—of Bavencio® (avelumab), a pharmaceutical owned by Merck. None of these funds are being, or will be, used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.